Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relacorilant DDI Study in Healthy Subjects
NCT03457597Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Mar 2018
- Primary completion
- Apr 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of relacorilant in Cushing's syndrome and ovarian cancer, sponsored by Corcept Therapeutics. Primary endpoint: Area under plasma concentration-time curve up to the last quantifiable sample. Started Mar 2018; status: completed.
02
Drugs
relacorilant
03
Conditions
Cushing's syndromeovarian cancer
Beyond the preview
Go deeper on NCT03457597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03457597.